Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

ONTOLOGY REPORT - ANNOTATIONS


Term:EC 5.99.1.2 (DNA topoisomerase) inhibitor
go back to main search page
Accession:CHEBI:50276 term browser browse the term
Definition:A topoisomerase inhibitor that inhibits the bacterial enzymes of the DNA topoisomerases, Type I class (EC 5.99.1.2) that catalyze ATP-independent breakage of one of the two strands of DNA, passage of the unbroken strand through the break, and rejoining of the broken strand. These bacterial enzymes reduce the topological stress in the DNA structure by relaxing negatively, but not positively, supercoiled DNA.
Synonyms:related_synonym: DNA topoisomerase inhibitor;   DNA topoisomerase inhibitors;   EC 5.99.1.2 (DNA topoisomerase) inhibitors;   EC 5.99.1.2 inhibitor;   EC 5.99.1.2 inhibitors;   topoisomerase I (EC 5.99.1.2) inhibitor;   topoisomerase I (EC 5.99.1.2) inhibitors;   topoisomerase I inhibitor;   topoisomerase I inhibitors;   type I DNA topoisomerase inhibitor;   type I DNA topoisomerase inhibitors


show annotations for term's descendants       view all columns           Sort by:
 





Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 19748
    role 19695
      biological role 19693
        biochemical role 19191
          enzyme inhibitor 18089
            EC 5.* (isomerase) inhibitor 5740
              EC 5.99.* (other isomerases) inhibitor 5550
                EC 5.99.1.* (miscellaneous isomerase) inhibitor 5550
                  topoisomerase inhibitor 5550
                    EC 5.99.1.2 (DNA topoisomerase) inhibitor 3727
                      (R)-homocamptothecin + 0
                      (S)-scoulerine + 0
                      SN-38 + 685
                      amarogentin 3
                      camptothecin 194
                      diflomotecan 0
                      dihydrobetulinic acid 0
                      disulfiram 568
                      ellagic acid + 123
                      feruloylagmatine + 0
                      irinotecan 685
                      irinotecan hydrochloride (anhydrous) + 0
                      irinotecan hydrochloride hydrate 0
                      kaempferol 3-O-(5-O-acetyl-alpha-D-apiofuranosyl)-7-O-alpha-L-rhamnopyranoside 0
                      kaempferol 3-O-[alpha-L-rhamnopyranosyl(1->2)-beta-D-galactopyranosyl]-7-O-alpha-L-rhamnopyranoside 0
                      kaempferol 3-O-[alpha-L-rhamnopyranosyl(1->2)-beta-D-glucopyranosyl]-7-O-alpha-L-rhamnopyranoside 0
                      kaempferol 3-O-alpha-L-arabinopyranosyl-7-O-alpha-L-rhamnopyranoside 0
                      kaempferol 3-O-beta-D-galactopyranosyl-7-O-alpha-L-rhamnopyranoside 0
                      kaempferol 3-O-beta-D-glucopyranosyl-7-O-alpha-L-rhamnopyranoside 0
                      lucanthone + 193
                      manoalide 3
                      methyl brevifolincarboxylate 0
                      morin 82
                      rubitecan 17
                      saintopin 0
                      topopyrone A 0
                      topopyrone B 0
                      topopyrone C 0
                      topopyrone D 0
                      topotecan 2700
paths to the root

NHLBI Logo

RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.